Skip to main content
Sign In

University of Colorado Cancer Center

University of Colorado Cancer Center, A National Cancer Institute-designated Comprehensive Cancer Center
 

Lung Cancer Ponatinib Trial


D. What do I do now?

Please answer the following questions to see if you may be eligible for the initial molecular screening phase – our contact details will then be provided at the end for those who are potentially eligible. ​​

1. Do you have advanced lung cancer (cancer that started in your lungs and has spread to either the other lung, the lining of your lungs, around your heart, to skin, muscle, and/or to other areas outside of your chest)?

Yes No

2. Did you have a biopsy or biopsies taken of your cancer? (If there is inadequate material when we review the sample we will inform you and your named MD about the pros and cons of a rebiopsy)

Yes No

3. If your cancer was found to be positive for one of the markers we test for would you be able (physically and financially including insurance coverage of care) to travel to Colorado for clinical trial treatment?

Yes No

4. Do you have the adenocarcinoma type of non small cell lung cancer?

Yes No Don't Know

5. Has your cancer been tested for the EGFR mutation?

Yes No Don't Know

7. You have told us you do not have an EGFR mutation in your cancer. Has your cancer been tested for an ALK rearrangement (to see whether it is ALK positive)?

Yes No Don't Know

8. You have told us you do not have an EGFR mutation in your cancer and your cancer has been tested for an ALK rearrangement (to see whether it is ALK positive). What was the ALK result?

ALK rearrangement present (ALK positive) No ALK rearrangement present (ALK wildtype) INSUFFICIENT TISSUE to complete analysis

9. You have told us your cancer has NOT been tested for an EGFR mutation. Has your cancer been tested for an ALK rearrangement (to see whether it is ALK positive)?

Yes No Don't Know

10. You have told us your cancer has not been tested for an EGFR mutation but has been tested for an ALK rearrangement (to see whether it is ALK positive). What was the ALK result?

11. You have told us there was insufficient tissue to determine if there was an EGFR mutation in your cancer. Has your cancer been tested for an ALK rearrangement (to see whether it is ALK positive)?

Yes No Don't Know

12. You have told us there was insufficient tissue to determine if there was an EGFR mutation in your cancer but your cancer has been tested for an ALK rearrangement (to see whether it is ALK positive). What was the ALK result?

ALK rearrangement present (ALK positive) No ALK rearrangement present (ALK wildtype) INSUFFICIENT TISSUE to complete analysis

a. You may qualify for biomarker prescreening for this study. Please contact us for more information. Please provide the patient's name (or your name if you are the patient), date of birth, and preferred form of contact.

Reset

b. You may or may not qualify. Adenocarcinomas can qualify but we need to know that you have an adenocarcinoma that does NOT have either an EGFR mutation or an ALK rearrangement. Please contact us so that we can provide a letter recommending this approach that you can show to your treating doctor. Please provide the patient's name (or your name if you are the patient), date of birth, and preferred form of contact. If the result is that you do NOT have an EGFR mutation or an ALK rearrangement please reapply.

Reset

c. We think it is more important your cancer is tested for ALK than trying for this study at present. Please contact us so that we can provide a letter recommending this approach that you can show to your treating doctor. Please provide the patient's name (or your name if you are the patient), date of birth, and preferred form of contact. If the result is that you do NOT have an ALK rearrangement please reapply.

Reset

d. We think it is more important your cancer is tested for an EGFR mutation than trying for this study at present. Please contact us so that we can provide a letter recommending this approach that you can show to your treating doctor. Please provide the patient's name (or your name if you are the patient), date of birth, and preferred form of contact. If the result is that you do NOT have an ALK rearrangement please reapply. If the result is that you do NOT have an EGFR mutation please reapply.

Reset

e. We think it is more important your cancer is tested for ALK and EGFR than trying for this study at present. Please contact us so that we can provide a letter recommending this approach that you can show to your treating doctor. Please provide the patient's name (or your name if you are the patient), date of birth, and preferred form of contact. If the result is that you do NOT have an EGFR mutation or an ALK rearrangement please reapply.

Reset

f. You may or may not qualify. Adenocarcinomas can qualify but we need to know that you have an adenocarcinoma that does NOT have either an EGFR mutation or an ALK rearrangement. As there is insufficient tissue to know this at present please contact us so that we can provide a letter explaining the pros and cons of a rebiopsy to allow additional testing that you can show to your treating doctor. Please provide the patient's name (or your name if you are the patient), date of birth, and preferred form of contact. If the result is that you do NOT have either an EGFR mutation or an ALK rearrangement please reapply.

Reset

g. Thank you for answering these prescreening questions. It appears that this study may not be for you. If you think this may be a mistake please contact us. Please provide the patient's name (or your name if you are the patient), date of birth, and preferred form of contact.

Reset
​​

© The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.